MedTrace Logo

Use of Ranibizumab With Mitomycin C During Trabeculectomy

NCT00661583 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-10-13

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.

Conditions

Interventions

DRUG

Ranibizumab

0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed

DRUG

Ranibizumab and MMC

Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy

DRUG

MMC

MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Malik Y. Kahook, MD · Rocky Mountain Lions Eye institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00661583 on ClinicalTrials.gov